JD Supra

Federal Court upholds validity of patent relating to paliperidone palmitate

On August 23, 2022, the Federal Court issued its public judgment and reasons in two actions under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”) ...
Monthly Prescribing Reference

Erzofri Now Available for Schizophrenia, Schizoaffective Disorder

The extended-release delivery coupled with the 351mg dose allows for single-dose initiation. Erzofri ® (paliperidone palmitate) extended-release injectable suspension is now available for the ...
Medscape

Onset of Efficacy and Tolerability Following the Initiation Dosing of Long-acting Paliperidone Palmitate

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in the ...
Monthly Prescribing Reference

Erzofri Approved for Schizophrenia, Schizoaffective Disorder

Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection. The Food and Drug Administration (FDA) has approved Erzofri ® (paliperidone palmitate) ...
JD Supra

Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment

In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
MedPage Today

Low Relapse Rates With Twice-Yearly Schizophrenia Treatment

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Hi everyone, I'm ...